Agenda for Day 3 - Wednesday 11 November, 2026
- Jennifer Smith-Parker - Director of Insights, BioSpace
Location: Biomanufacturing Strategy Stage
- Explores how partnerships between Big Pharma, SMEs, and suppliers can address sustainability challenges across the biopharma value chain.
Highlights industrial challenges that requires transformative technologies for reducing environmental impact.
Tackles Scope 3 GHG emissions and the increasing environmental demands on suppliers, offering scalable solutions for deep decarbonization.
Showcases a proven innovation ecosystem that accelerates technology development from TRL 4 to TRL 9, fostering cross-sectoral collaboration.
Discusses next-generation partnership models and public-private collaborations.
Provides actionable insights into sustainable innovation, balancing operational efficiency with environmental responsibility to drive long-term growth
- Magnus Bjorsne - Executive Director AZ BioVenture Innovation Unit & CEO AZ BioVentureHub AB, AstraZeneca
Location: Biomanufacturing Strategy Stage
Developing strategic alliances with CDMOs and biopharma companies to accelerate growth and innovation.
Exploring scalable and adaptable models tailored to the needs of emerging companies.
Securing funding and optimizing resources to support growth and innovation.
Overcoming regulatory hurdles and aligning with industry standards to ensure compliance and efficiency.
Driving technological advancements and differentiation through co-development opportunities.
Case studies of successful strategies leading to breakthrough therapies
- Massimiliano Cesarini - CEO, Biogenera SpA
Location: Biomanufacturing Strategy Stage
Just-Evotec Biologics has established an integrated development and manufacturing platform that combines intelligent candidate optimization with highly intensified bioprocessing to support rapid advancement of biologics from cell line development through early clinical manufacturing. High cell density culture enables efficient production of low-expressing proteins, while shortened process residence times contribute to consistent product quality. The platform is particularly well suited for increasingly complex biologics, including bispecific and multi-specific antibodies, offering a scalable and accelerated route to early clinical evaluation.
- Nick Hutchinson - Associate VP, Business Development, Just - Evotec Biologics
Location: Biomanufacturing Strategy Stage
How can breakthrough innovation become scalable, GMP-ready biomanufacturing? Bringing together biotech, translational research and CDMO perspectives across emerging therapeutic technologies, this panel explores the challenges of process development, scale-up and industrialisation - and the partnerships needed to transform scientific advances into robust, manufacturable and commercially viable products.
- David Honba - COO, BioWin, Health Innovation Cluster of Wallonia
- Vincent Bischoff - COO, Superbranche
- Jason Conner - CEO, Cellistic
- Thomas Schmid - Head of GMP Biopharmaceuticals, Fraunhofer IZI
Location: Biomanufacturing Strategy Stage
This fireside chat will feature industry leaders who have successfully co-developed innovative therapies, sharing their experiences, challenges, and the transformative impact of collaboration on innovation. Key discussion points include:
Co-development models for advancing therapies through strategic partnerships
Joint ventures as a catalyst for technology innovation in the CDMO landscape
Strategies to foster open innovation and drive collaborative breakthroughs
Addressing challenges in collaborative R&D and ensuring alignment across stakeholders
Case studies highlighting successful co-innovation projects and their outcomes
A forward-looking perspective on the future of collaborative innovation in CDMO partnerships
- Denes Zalai - Director Technology, Eleva Biologics
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator, Bayer
- Ashiq Khan - CCO, Evotec
Location: Biomanufacturing Strategy Stage
A forward-looking address that synthesizes the conference themes and challenges industry leaders to think boldly about the future. Explore emerging trends, disruptive innovations, and the collaborative mindset needed to shape the next era of biomanufacturing excellence.
Future-proofing manufacturing capabilities to adapt to evolving market demands, regulatory landscapes, and technological disruptions
Creating resilient supply chains that ensure business continuity in the face of challenges
The impact of emerging technologies on biomanufacturing processes and efficiency
Market consolidation trends and their implications for the biomanufacturing landscape
Pioneering Access for Patients: building and end-to-end Biosimilar pipeline
Next-generation models for scaling and optimizing biomanufacturing operations
Breakthroughs in drug delivery systems and their integration into biomanufacturing workflows
The role of AI and machine learning in enhancing biomanufacturing precision and decision-making
Predictions for the future of biomanufacturing, including opportunities for innovation and overcoming challenges
- Steven Howe - VP, Process Development, Resolution Therapeutics
- Michael Moehlen - VP Manufacturing Science & Technology and Service, Valneva
- Federico Pollano - CCO, IDT Biologika
- Michela Silacci Melkko - Senior Director, External Innovation, Johnson & Johnson
